"With a further stabilization of the situation, Fresenius Kabi also
expects a gradual resumption of its sales force activities in
China," the company said in a statement on Tuesday.
It added it had not suffered a major interruption of production,
allowing it to supply pharmaceuticals and medical devices in China.
(Reporting by Ludwig Burger; editing by Scot W. Stevenson)
[© 2020 Thomson Reuters. All rights
Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.